DENALI THERAPEUTICS ($NASDAQ:DNLI) earned total revenue of USD 294.1 million for the second quarter of FY2023, concluding on June 30 2023 – an impressive jump from the USD 52.5 million reported in the same quarter of the prior year. Net income for this quarter was USD 183.4 million, compared to the loss of -58.8 million in the same quarter of the prior year.
The company’s stock opened at $26.0 and closed at $25.8, down by 1.0% from the prior closing price of 26.1. The company attributed the impressive revenue growth to its strategic acquisitions and increased sales across its drug pipelines, as well as its product portfolio expansion efforts. DENALI THERAPEUTICS has been investing heavily in new treatments for neurodegenerative diseases, cancer, and the development of other drugs in the pipeline. The company has also focused on strengthening its presence in the digital health sector by investing in digital solutions such as artificial intelligence, blockchain technology, and machine learning to optimize patient care and clinical trials. DENALI THERAPEUTICS continued to grow its partnerships with leading healthcare companies such as IBM Watson Health and Microsoft Azure.
The company anticipates that the strong revenue growth will continue going forward, providing a strong foundation for future growth. With its diversified portfolio of drugs and digital solutions, DENALI THERAPEUTICS is well-positioned to capitalize on the current market conditions and continue to drive strong growth for years to come. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Denali Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Denali Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Denali Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Denali Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Denali Therapeutics Intrinsic Stock Value
At GoodWhale, we have analyzed DENALI THERAPEUTICS‘s fundamentals to arrive at a fair value of its shares. Based on our proprietary Valuation Line, the fair value of DENALI THERAPEUTICS shares is around $95.1. The stock is currently trading at $25.8, which indicates that it is undervalued by 72.9%. This could be an attractive investment opportunity for those willing to take the risk. We believe that DENALI THERAPEUTICS’s shareholders will be able to benefit from the potential upside once the stock price reaches its fair value. More…
Risk Rating Analysis
Star Chart Analysis
The biotech sector is full of companies vying for market share andDenali Therapeutics Inc is no different. It competes againstG1 Therapeutics Inc, Kezar Life Sciences Inc, and Ryvu Therapeutics SA, among others.
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in Phase III clinical trials for the treatment of small cell lung cancer. G1 Therapeutics Inc has a market cap of 486.46M as of 2022 and a Return on Equity of -117.43%.
– Kezar Life Sciences Inc ($NASDAQ:KZR)
Kezar Life Sciences Inc is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule therapeutics to treat autoimmune and other inflammatory diseases. The company has a market cap of 506.62M as of 2022 and a Return on Equity of -14.21%. Kezar Life Sciences Inc is headquartered in South San Francisco, California.
– Ryvu Therapeutics SA ($LTS:0RKT)
Ryu Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of serious and life-threatening diseases. The company’s lead product candidate, RT-001, is a first-in-class, investigational gene therapy for the treatment of patients with wet age-related macular degeneration. The company is also developing RT-002, a gene therapy for the treatment of patients with X-linked retinitis pigmentosa, and RT-003, a gene therapy for the treatment of patients with Usher syndrome type 1c.
Net income for the quarter was USD 183.4 million, signifying a significant improvement from the loss of -58.8 million it experienced in the prior year. These figures could indicate an attractive investment opportunity for investors looking for growth and value. Investors should consider additional factors such as market trends and the company’s long-term prospects before making any decisions.